Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Tango Therapeutics, Inc. (TNGX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$20.87-9.97%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for TNGX yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Progress clinical trials of vopimetostat, especially with RAS(ON) inhibitors | A primary condition in Tango Therapeutics, Inc.'s published investment case. The stated target is Continue advancing trials with positive data and regulatory progress. | Improving | Trial progress stalls or negative data emerges within next year | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk clinical-stage biotechnology company, with value tied to research progress rather than current earnings. Its multi-year view is still at a watch stage: clinical evidence has advanced, but key trial plans remain in progress and recent results have been weak.
The valuation model points to a premium versus peers, while its confidence is low and the expectations gap is substantial. The evidence suggests some value is being assigned to future pipeline potential, but the premium is not clearly supported by current financial performance.
Near term, TNGX is likely to remain loss-making as it funds research and clinical programs; its latest reported quarterly net loss widened year over year, while research spending increased. Cash and marketable securities rose in the reported balance and management expects the June balance to fund its current operating plan, but the recent earnings miss and consecutive-miss pattern make the next results a key risk.
The multi-year thesis depends on advancing vopimetostat toward a planned Phase 3 pancreatic cancer trial and delivering on broader pipeline milestones. Near term, a guidance cut or weaker employment data could add pressure, while continued strength from major healthcare companies could support the sector backdrop. The October clinical response and progression-free survival results are encouraging evidence, but they do not establish completion of the planned trial.
Over the next 1 to 3 years, TNGX remains a high-risk development story with stronger funding capacity and promising clinical evidence, but weak financial performance and incomplete milestones leave the thesis unsettled. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Control operating losses near or below -$49 million per quarter |
| Despite losses, management aims to control operating costs. |
| Under Pressure |
| Operating losses worsen beyond -$49 million per quarter in FY26 |
Operating income: $-59.785M FY2026-Q2; GAAP. Published target: Operating income no worse than -$49 million per quarter. Annual target cannot be compared with a quarterly or TTM observation. Aug 11, 2026-59,785,000 USD · source valueLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Maintain sufficient capital to fund clinical trials and operations | The company secured $600 million in capital to fund operations. | Intact | Failure to secure capital leading to operational constraints | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-1.52 → $-1.68 · observed estimates
$0.00B → $0.00B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-1.52 | $2,855,090 | 11 / 11 |
| 2026-07-25 | $-1.52 | $2,855,090 | 11 / 11 |
| 2026-07-26 | $-1.52 | $2,855,090 | 11 / 11 |
| 2026-07-27 | $-1.52 | $2,855,090 | 11 / 11 |
| 2026-07-28 | $-1.52 | $2,855,090 | 11 / 11 |
| 2026-07-29 | $-1.49 | $3,488,889 | 10 / 7 |
| 2026-07-30 | $-1.52 | $2,855,090 | 11 / 11 |
| 2026-07-31 | $-1.49 | $3,488,889 | 10 / 7 |
| 2026-08-01 | $-1.49 | $3,488,889 | 10 / 7 |
| 2026-08-02 | $-1.52 | $2,855,090 | 11 / 11 |
| 2026-08-03 | $-1.52 | $2,855,090 | 11 / 11 |
| 2026-08-04 | $-1.52 | $2,855,090 | 11 / 11 |
| 2026-08-05 | $-1.49 | $3,488,889 | 10 / 7 |
| 2026-08-06 | $-1.52 | $2,855,090 | 11 / 11 |
| 2026-08-08 | $-1.52 | $2,855,090 | 11 / 11 |
| 2026-08-09 | $-1.52 | $2,855,090 | 11 / 11 |
| 2026-08-10 | $-1.49 | $3,488,889 | 10 / 7 |
| 2026-08-12 | $-1.49 | $3,488,889 | 10 / 7 |
| 2026-08-13 | $-1.49 | $3,488,889 | 10 / 7 |
| 2026-08-14 | $-1.49 | $3,488,889 | 10 / 7 |
| 2026-08-15 | $-1.49 | $3,488,889 | 10 / 7 |
| 2026-08-16 | $-1.49 | $3,488,889 | 10 / 7 |
| 2026-08-17 | $-1.49 | $3,488,889 | 10 / 7 |
| 2026-08-18 | $-1.49 | $3,488,889 | 10 / 7 |
| 2026-08-19 | $-1.49 | $3,488,889 | 10 / 7 |
| 2026-08-20 | $-1.66 | $3,140,000 | 11 / 8 |
| 2026-08-21 | $-1.66 | $3,140,000 | 11 / 8 |
| 2026-08-22 | $-1.66 | $3,140,000 | 11 / 8 |
| 2026-08-23 | $-1.66 | $3,140,000 | 11 / 8 |
| 2026-08-24 | $-1.66 | $3,140,000 | 11 / 8 |
| 2026-08-25 | $-1.66 | $3,140,000 | 11 / 8 |
| 2026-08-26 | $-1.66 | $3,140,000 | 11 / 8 |
| 2026-08-27 | $-1.66 | $3,140,000 | 11 / 8 |
| 2026-08-28 | $-1.66 | $3,140,000 | 11 / 8 |
| 2026-08-29 | $-1.66 | $3,140,000 | 11 / 8 |
| 2026-08-30 | $-1.66 | $3,140,000 | 11 / 8 |
| 2026-08-31 | $-1.66 | $3,140,000 | 11 / 8 |
| 2026-09-01 | $-1.66 | $3,140,000 | 11 / 8 |
| 2026-09-02 | $-1.66 | $3,140,000 | 11 / 8 |
| 2026-09-03 | $-1.66 | $3,140,000 | 11 / 8 |
| 2026-09-04 | $-1.66 | $3,140,000 | 11 / 8 |
| 2026-09-05 | $-1.66 | $3,140,000 | 11 / 8 |
| 2026-09-06 | $-1.66 | $3,140,000 | 11 / 8 |
| 2026-09-07 | $-1.66 | $3,140,000 | 11 / 8 |
| 2026-09-08 | $-1.66 | $3,140,000 | 10 / 7 |
| 2026-09-09 | $-1.70 | $3,488,889 | 10 / 7 |
| 2026-09-10 | $-1.70 | $3,488,889 | 10 / 7 |
| 2026-09-11 | $-1.70 | $3,488,889 | 10 / 7 |
| 2026-09-12 | $-1.70 | $3,488,889 | 10 / 7 |
| 2026-09-13 | $-1.70 | $3,488,889 | 9 / 7 |
| 2026-09-14 | $-1.70 | $3,488,889 | 9 / 7 |
| 2026-09-15 | $-1.70 | $3,488,889 | 9 / 7 |
| 2026-09-16 | $-1.70 | $3,488,889 | 9 / 7 |
| 2026-09-17 | $-1.70 | $3,488,889 | 9 / 7 |
| 2026-09-18 | $-1.70 | $3,488,889 | 9 / 7 |
| 2026-09-19 | $-1.70 | $3,488,889 | 9 / 7 |
| 2026-09-20 | $-1.70 | $3,488,889 | 9 / 7 |
| 2026-09-21 | $-1.70 | $3,488,889 | 9 / 7 |
| 2026-09-22 | $-1.70 | $3,488,889 | 9 / 7 |
| 2026-09-23 | $-1.70 | $3,488,889 | 9 / 7 |
| 2026-09-24 | $-1.70 | $3,488,889 | 9 / 7 |
| 2026-09-25 | $-1.70 | $3,488,889 | 9 / 7 |
| 2026-09-26 | $-1.70 | $3,440,000 | 9 / 7 |
| 2026-09-27 | $-1.70 | $3,440,000 | 9 / 7 |
| 2026-09-28 | $-1.70 | $3,440,000 | 9 / 7 |
| 2026-09-29 | $-1.70 | $3,440,000 | 9 / 7 |
| 2026-09-30 | $-1.70 | $3,440,000 | 9 / 7 |
| 2026-10-01 | $-1.70 | $3,440,000 | 9 / 7 |
| 2026-10-02 | $-1.70 | $3,440,000 | 9 / 7 |
| 2026-10-03 | $-1.70 | $3,440,000 | 9 / 7 |
| 2026-10-04 | $-1.70 | $3,440,000 | 9 / 7 |
| 2026-10-05 | $-1.70 | $3,440,000 | 9 / 7 |
| 2026-10-06 | $-1.70 | $3,440,000 | 9 / 7 |
| 2026-10-07 | $-1.70 | $3,440,000 | 9 / 7 |
| 2026-10-08 | $-1.70 | $3,440,000 | 9 / 7 |
| 2026-10-09 | $-1.70 | $3,440,000 | 9 / 7 |
| 2026-10-10 | $-1.70 | $3,440,000 | 9 / 7 |
| 2026-10-11 | $-1.70 | $3,440,000 | 9 / 7 |
| 2026-10-12 | $-1.70 | $3,440,000 | 9 / 7 |
| 2026-10-13 | $-1.70 | $3,440,000 | 9 / 7 |
| 2026-10-14 | $-1.70 | $3,440,000 | 9 / 7 |
| 2026-10-15 | $-1.70 | $3,440,000 | 9 / 7 |
| 2026-10-16 | $-1.67 | $3,127,273 | 9 / 7 |
| 2026-10-17 | $-1.67 | $3,127,273 | 9 / 7 |
| 2026-10-18 | $-1.67 | $3,127,273 | 10 / 8 |
| 2026-10-19 | $-1.67 | $3,127,273 | 10 / 8 |
| 2026-10-20 | $-1.67 | $3,127,273 | 10 / 8 |
| 2026-10-21 | $-1.67 | $3,127,273 | 10 / 8 |
| 2026-10-22 | $-1.67 | $3,127,273 | 10 / 8 |
| 2026-10-23 | $-1.67 | $3,127,273 | 10 / 8 |
| 2026-10-24 | $-1.68 | $3,127,273 | 10 / 8 |
| 2026-10-25 | $-1.68 | $3,127,273 | 10 / 8 |
| 2026-10-26 | $-1.68 | $3,127,273 | 10 / 8 |
| 2026-10-27 | $-1.68 | $3,127,273 | 10 / 8 |
| 2026-10-28 | $-1.68 | $3,127,273 | 9 / 8 |
| 2026-10-29 | $-1.68 | $3,127,273 | 9 / 8 |
| 2026-10-30 | $-1.68 | $3,127,273 | 9 / 8 |
| 2026-10-31 | $-1.68 | $3,127,273 | 9 / 8 |
| 2026-11-01 | $-1.68 | $3,127,273 | 9 / 8 |
| 2026-11-02 | $-1.68 | $3,127,273 | 9 / 8 |
| 2026-11-03 | $-1.68 | $3,127,273 | 9 / 8 |
| 2026-11-04 | $-1.68 | $3,127,273 | 9 / 8 |
| 2026-11-05 | $-1.68 | $3,127,273 | 9 / 8 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 12 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell
Recent actions · Oct 7–Nov 5 · 1 recorded
1 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 7, 2026–Nov 5, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.